YEAR EVENTS 1984 - Panacea Biotec Ltd. was incorporated as a private limited company in the name and style of Panacea Drugs Private Ltd. on 2nd February. Subsequently the Company became deemed Public limited Company u/s 43A(1 A) of the Companies Act, 1956 w.e.f. 30.6.93. - The Company is engaged in 4 product lines of Pharmaceuticals are Vaccines, Biologicals, formulations, Natural Products. - The Company has been promoted by Mr. Sosh, Kumar Jain, who is a pharmacist having about 40 years of experience in the pharmaceutical industry. 1993 - The name of the Company changed to Panacea Biotec Limited on 7th September. - The Company now proposes to expand the capacity of Vaccines Division, along with an expansion in the capacities of capsules and suspensions. 1994 - The Company is using technology developed in-house and is not entering into any technical collaboration as it has adequate technical expertise. 1995 - During the year the company is public issue of 21,28,000 No. of Equity Shares of Rs. 10/- each for cash at a premiumof Rs. 50/- per share aggregating Rs. 1276/80 Lacs, and reservation of 6,72,000 No. of Equity Shares of Rs. 10/- each for cash at a premium of Rs. 50/- per share aggregating Rs. 4,03,20,000 for firm allotment to NRIs/OCB's. 1996 - The Company has successfully commissioned a state-of-the-art Viral Vaccine Research facility at Latru near Chandigarh. 1997 - Panacea Biotec (PBL) has been going global with a gusto. It has introduced some speciality formulations like Nimulid and, two of these are under worldwide patent in PBL's name with applications filed in 72 countries. 1999 - During the year under review, the Company had allotted 50,00,000 - 12% Redeemable Cumulative Preference Shares of Rs.10/- each aggregating Rs.5.00 Crores to Industrial Development Bank of India on private placement basis. 2000 - Panacea Biotech Ltd, a pharmaceutical company in North India, is exploring opportunities for growth through expansion, diversification and backward integration. - The company has proposed an amendment in articles of association for implementing the depository system for its stocks. - The company's various product introductions like Nimulid, Livoluc, Nimulid gel, Risipid etc have been well received in the market. - Panacea Biotec Ltd (PBL) has entered into a joint venture with Heber Biotec Ltd (HBL) of Cuba to manufacture Hepatitis-B vaccine in bulk form. A new company - Pan Heber Biotec Ltd - has been formed for the purpose in which the two partners hold equal stake. - The company is setting up another plant at Lalru to manufacture branded formulations for the export market. - The company is planning to launch an anti-histamine drug in June this year. - Panacea Biotech has set up two wholly-owned subsidiary companies in the UK and Hong Kong with the objective of importing and exporting pharmaceutical, technology and other products. - The Company has entered into agreement with NSDL and CDSL for dematerialisation. 2001 - Panacea Biotec Ltd (PBL), a Delhi-based pharma company, has recently signed an agreement with National Research Development Corporation (NRDC) to commercialise the know-how for an opthalmic formulation of ocular delivery, using nanotechnology. 2002 -Appoints Mr Rajesh Jain and Mr Sandeep Jain as the Joint Managing Directors of the company. -Files for worldwide patent for its new NDDS for an anti-TB combination drug. -Board approves for the subdivision of shares from Rs.10 per share of Re.1 per share , and also decides to wind up the company's wholly owned subsidiary at Isle of Man, UK. -Company's non-executive director makes a gift of 2,01,000 shares of Re.1 each representing 0.35% of the company's total capital. -Commences marketing of herbal and dietary supplement products under its SBU viz. "Best on Health" and launches ThankGod capsules, ThankGod Anytime cream, ThankGod pain & Itch relief cream etc. 2003 -Stock split from Rs 10 per equity share to Rs 1 per equity share - Panacea Biotec forays OTC market with Herbal Products 2004 -California-based Chiron Vaccines, the world's 5th largest vaccine producer, has struck a deal with Delhi-based Panacea Biotec to set up a joint venture in India -Panacea Biotec launches new product HEARTFELT, natural therapy for cholesterol management developed by its Research & Development Team. -Panacea rolls out new nimesulide injection -Launches Combination vaccines through JV with Chiron Vaccines, UK on November 24, 2004 2005 -Panacea Biotec launches 'Upright' for effective relief from severe pain & inflammation -Panacea Biotec introduces Noval Anti-allergy Drug - Ralif 2006 -Panacea Biotec enters into an agreement with PT Bio Farma to manufacture Measles Vaccine 2007 - Panacea Biotec signs agreement with Family Vaccines to supply combination vaccines 2009 - Panacea Biotec - EasyFive Injects; USD 222.37 million Award by UNICEF 2010 - Panacea Biotech's Baddi unit gets US FDA approval - Panacea Bio - Board recommends Dividend of Re. 0.25 (25%) each on Equity Shares of the Company, for the financial year 2009-10. 2011 - PanaceBiotec - Panacea Biotec Launches - PacliALL - Panacea Biotec announced that the company is mulling to foray into healthcare infrastructure sector with setting up of multi specialty hospital in Gurgaon, Haryana. 2012 - PanaceBiotec - Panacea Biotec celebrates 63rd Indian Republic day with launch of "POLPROTEC" in Nigeria". - Panacea Biotech launches Inactivated Polio Virus vaccine in Nigeria - PanaceBiotec - Panacea Biotec inaugurates state of the art Oncology Production Unit - PanaceBiotec - Panacea Biotec Entered into Strategic Alliance with Osmotica Pharmaceutical - Panacea Biotec wins order worth Rs 187 cr from Govt to supply polio vaccines 2013 -Panacea Biotec Ltd has opened up its wholly owned subsidiary in UAE in the name of Panol Industries. 2014 -Panacea Biotec Ltd has entered into collaboration with a leading International Pharmaceutical Company for the development and supply of an immunosuppressant generic product in USA. - "Panacea Biotec Announces Collaboration with Rising Pharmaceuticals Inc.". -Company has received UNICEF Award for supply of Companys DTB-HebB-Hib (Pentavalent) Vaccine Easyfive-TT to UNICEF. 2015 -Panacea Biotec Gets Pan American Health Organization (PAHO) order for supply of EasyFive-TT Vaccines worth 2016 -"Panacea Biotec Launches - CABAPAN, A Cost Effective product for the treatment of metastatic Castration Resistant Prostrate Cancer (mCRPC)". -Panacea Biotec Receives Prestigious Intellectual Property & Science Award "Top 50 Indian Innovators 2015"". -Panacea Biotec Launches - TENEPAN, a cost effective product for the treatment of Type 2 Diabetes Mellitus (T2DM)". -"Panacea Biotec Introduces World's First Fully Liquid Tetravalent Vaccine Easyfour-TT against DTP and Hib". 2017 -Panacea Biotec Introduces World's First Fully Liquid Hexavalent Combination Vaccine EasySixTM for Six Preventable Diseases. -Panacea Biotec announces ANDA approval for US Market and LTA & Award from UN Agencies for Supply of Pentavalent Vaccine (Easyfive-TT). -Panacea Biotec Announces Joint Collaboration with Bionpharma Inc. 2018 -Panacea Biotec inks Tripartite Agreement with Natco Pharma Ltd. and Breckenridge Pharmaceutical Inc. for manufacturing and supply of Azacitidine injection in the U.S. Market. 2019 -Panacea Biotec Announces Launch Of ViLACT For Treatment Of Uncontrolled Type 2 Diabetes Mellitus Patients. -Panacea Biotec receives USD 24.32 Million Award of Pentavalent Vaccine from U.N. Agencies. 2021 -RDIF and Panacea Biotec launch the production of Sputnik V in India. -Panacea Biotec supplies 1st shipment of the second component of Sputnik V vaccine produced in India. 2022 -Panacea Biotec receives UNICEF & PAHO awards for supply of Pentavalent Vaccine.. -CEPI, THSTI and Panacea Biotec partner to develop broadly protective Betacoronavirus vaccines. 2023 -Panacea Biotec launches EasyFourPol in India and receives registration of Valganciclovir Powder for Oral Solution in Germany. - Panacea Biotec Launches Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound), a genericversion of Abraxane. -Launch of new range of high-quality pediatric food & nutritional products in India by Company's wholly owned subsidiary, Panacea Biotec Pharma Limited '. 2024 -The Company has received a Letter of Award from UNICEF for supply of 115 million doses of its bivalent oral polio vaccine (bOPV) worth US$ 14.95 million.